ELEXACAFTOR | ELEXACAFTOR | ATC R07AX32
RESPIRATORY SYSTEM TREATMENT OF CYSTIC FIBROSIS (CF) THE COMBINED EFFECT OF ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR IS INCREASED QUANTITY AND FUNCTION OF F508DEL-CFTR AT THE CELL SURFACE ELEXACAFTOR AND TEZACAFTOR BIND TO DIFFERENT SITES ON THE CFTR PROTEIN | ORAL | Cmax 14.6 MICROMOLAR Tmax 6 HOUR F 80 PERCENT VD 53.7 LITER PPB 99 PERCENT Cl 1.18 LITER / HOUR HT 29.8 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER (<1 MG/ML) | CFTR CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PDB 8EIQ (THE COMPLEX OF PHOSPHORYLATED HUMAN DELTA F508 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH TRIKAFTA [ELEXACAFTOR (VX-445), TEZACAFTOR (VX-661), IVACAFTOR (VX-770)] AND ATP, MG) LIGAND CODE = WJX (link to the list of PDB complexes) Download experimental 3D coordinates of WJX with added hydrogens | Cystic fibrosis transmembrane conductance regulator UNIPROT P13569 CFTR more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |